Company intelligence / Profile preview

PanThera Biopharma

Seoul, Seoul, South Korea

Ownership: Private
Employees: ~20
Development stage: Other

Overview

PanThera Biopharma is a South Korean biotechnology company specializing in the development of next-generation Targeted Alpha Therapy (TAT) for various cancers. The company leverages Actinium-225 (Ac-225), a high-energy alpha-emitting radioisotope, to create precision radiopharmaceuticals that selectively destroy cancer cells while minimizing damage to healthy tissue. Its lead programs include PTB-101 for prostate cancer and PTB-201 for FAP-expressing solid tumors. PanThera Biopharma has established strategic partnerships for the stable supply of Ac-225, positioning itself as a key player in the emerging radiopharmaceutical market in Asia.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalMonoclonal antibody
Industry: Biotech

Partnerships

PanThera (Belgium)

Beyond the preview

Go deeper on PanThera Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PanThera Biopharma.

Explore the full profile